NCT06435039View on ClinicalTrials.gov

A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

July 16, 2024

Study Completion Date

July 16, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

APL-1202

APL-1202 IR tablets.

DRUG

APL-1501

APL-1501 ER capsules.

Trial Locations (1)

2031

Scientia Clinical Research Ltd, Randwick

Sponsors

Lead Sponsor

Syneos Health
All Listed Sponsors
collaborator

Asieris Pharmaceuticals (AUS) Pty Ltd.

INDUSTRY

lead

Syneos Health

OTHER